Financial results: Bioxyne; Melodiol Global Health; Emyria; Zelira; Elixinol; Wellnex Life; Argent BioPharma by Steve Jones May 1, 2024May 1, 2024 Revenue generated by Breathe Life Sciences (BLS) slipped to A$1.7 million in Q3 FY24 with parent […]
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
BLS launches B2B trading platform CanxChange with $10m sales pipeline in week one by Martin Lane January 22, 2024July 11, 2024
Company news: Breathe Life Sciences; Cann Group; InhaleRx; X-Hemp; Green Farmers/Elevated Signals by Martin Lane October 19, 2023April 30, 2024
Financial results: Bioxyne/BLS; Emyria; Ecofibre; Zelira Therapeutics by Martin Lane October 3, 2023April 30, 2024
Bioxyne inks JV to launch AI-powered B2B platform in Australia by Martin Lane August 21, 2023April 30, 2024
ASX-listed Bioxyne launches telehealth platform BLS Clinics by Martin Lane June 21, 2023April 30, 2024
